106 results on '"Gordon, Stuart C."'
Search Results
2. Sequential PegIFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
3. Antiviral Treatment and Response are Associated With Lower Risk of Dementia Among Hepatitis C Virus-Infected Patients.
4. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
5. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients
6. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
7. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients
8. Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation
9. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010
10. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
11. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
12. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
13. WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
14. SAT-438 Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
15. LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study
16. OS-019 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results
17. THU-218 - Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
18. SAT-125 - Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry™ (GNR™)
19. THU-453 - Stigma in NAFLD and NASH: a global survey of patients and providers
20. WED-283 - Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD)
21. LBP-38 - Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
22. Mo1594 EVALUATION OF RACIAL DIFFERENCES IN ALKALINE PHOSPHATASE TRAJECTORY AND ANTI-MITOCHONDRIAL ANTIBODY POSITIVITY PRIOR TO DIAGNOSIS OF PRIMARY BILIARY CHOLANGITIS.
23. 3 EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS.
24. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
25. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
26. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
27. LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort
28. PS-122-Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients
29. Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C–Infected Patients in the United States.
30. Mo1517 CLINICALLY SIGNIFICANT PRURITUS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY ™ (GLR™).
31. Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
32. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
33. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium.
34. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
35. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population.
36. Hepatitis C Screening: Summary of Recommendations From the Clinical Decision Tool.
37. Treatment of HBV/HCV Coinfection: Releasing the Enemy Within.
38. Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival.
39. Sa313 CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY™.
40. 342 CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY.
41. FRI-023-Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response.
42. THU-308-More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/nonalcoholic steatohepatitis.
43. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.
44. Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems.
45. Su1027 - Direct Healthcare Costs Associated with Osteoporosis and Bone Fracture in Pharmacologically Treated Chronic Hepatitis B Patients: Results of A United States Population-Based Cohort Study.
46. 508 - Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR).
47. 429 - High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis.
48. 422 - MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure.
49. Sa1497 - The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in > 1,000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: An Integrated Analysis.
50. 509 - No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.